Headlands Technologies LLC Increases Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Headlands Technologies LLC grew its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 494.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,653 shares of the biopharmaceutical company’s stock after buying an additional 18,011 shares during the quarter. Headlands Technologies LLC’s holdings in TG Therapeutics were worth $652,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in TG Therapeutics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock valued at $469,454,000 after acquiring an additional 209,190 shares during the period. State Street Corp grew its holdings in shares of TG Therapeutics by 35.8% in the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after purchasing an additional 2,398,015 shares during the last quarter. Clearbridge Investments LLC bought a new stake in TG Therapeutics during the 4th quarter valued at about $55,237,000. Charles Schwab Investment Management Inc. lifted its holdings in TG Therapeutics by 7.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company’s stock valued at $38,212,000 after buying an additional 84,904 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in TG Therapeutics by 10.5% in the 4th quarter. Bank of New York Mellon Corp now owns 923,488 shares of the biopharmaceutical company’s stock valued at $27,797,000 after buying an additional 87,679 shares during the period. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on TGTX. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Trading Up 5.5 %

TGTX opened at $39.82 on Thursday. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The firm has a market cap of $6.25 billion, a price-to-earnings ratio of -398.16 and a beta of 2.13. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $43.32. The stock has a fifty day moving average price of $34.94 and a 200-day moving average price of $30.67.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. As a group, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.50% of the company’s stock.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.